Skip to main content
. Author manuscript; available in PMC: 2014 Jun 15.
Published in final edited form as: Cancer Res. 2013 Apr 10;73(12):3525–3533. doi: 10.1158/0008-5472.CAN-12-4244

Figure 1. Determination of minimal sufficient length of labeling phase.

Figure 1

All pulse data, expressed as the percentage of tumor cells that are BrdU-positive (%BrdU+). Times shown are the days since the first dose of BrdU administration began. We attempted to test a mono-exponential and a bi-exponential model for the pulse data, but the time period was insufficient to distinguish between the two models.